{"id":1023046,"date":"2026-11-20T16:35:55","date_gmt":"2026-11-20T21:35:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/"},"modified":"2026-11-20T16:35:55","modified_gmt":"2026-11-20T21:35:55","slug":"abivax-statement-on-short-seller-report","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/","title":{"rendered":"Abivax Statement on Short Seller Report"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        \n      <\/p>\n<p align=\"center\">\n        <b>Abivax Statement on Short Seller Report<\/b>\n      <\/p>\n<p align=\"justify\">\n        <b>PARIS, France \u2013 November 20, 2026 \u2013 10:30 PM CET<\/b> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=asWw3Utt4Nh9KDbJOSD3x40g99H8fE0TqkYM3Tcb2hN8Bn19n4Q5FnDl7GHM1Tt62Bdg5ySz-44NPqMzLAEpmQ==\" rel=\"nofollow\" target=\"_blank\">Abivax SA<\/a> (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax,\u201d the \u201cCompany,\u201d \u201cwe\u201d or \u201cour\u201d), a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026.<\/p>\n<p align=\"justify\">We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax\u2019s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself. We firmly stand behind the integrity of our clinical development program, including the results of our Phase 3 ABTECT trials and the strength of the clinical data generated to date, which will support Abivax\u2019s U.S. FDA NDA filing by the end of the year.<\/p>\n<p align=\"justify\">Notably, Scorpion Capital explicitly disclosed its short position in Abivax and its intention to begin covering a substantial portion of that position upon publication of its report, underscoring its direct financial interest in a decline in our share price. These direct financial incentives provide important context for evaluating the report.<\/p>\n<p align=\"justify\">\n        <b>About Abivax <\/b>\n      <\/p>\n<p align=\"justify\">Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax\u2019s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.<\/p>\n<p align=\"justify\">\n        <b>Contact:<\/b><br \/>\n        <br \/>Patrick Malloy<br \/>SVP, Investor Relations<br \/>Abivax SA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9aZ9LYIvgadJ_Xa5ldX4Jyk9VBVVIDNVdNlKB02MuauX7kQQy73-SlSfQ6Xaf7o0h8TOF23jKWkVjPr7XHKMN8FriYuuT2G2z0HAhV7x7TIkjlMyOSE4p105nJOJ7viS\" rel=\"nofollow\" target=\"_blank\">patrick.malloy@abivax.com<\/a><br \/>+1 847 987 4878<\/p>\n<p align=\"justify\">\n        <b>Media Contacts:<\/b><br \/>\n        <br \/>\n        <b>LifeSci Communications<br \/><\/b>Karissa Baltz, PhD<br \/>Associate Director<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EBSvKmRpXmJDAgs5V8AgtxSo9v_1jY-LZeHx6DhjAgaQ4-G34Y4pY75Wj37SVhjoNbsz84Gz8xBkkFNSUEDf2i5O9FmRBUpVJOwdz-rOmMR3E7eHA3gtX23JsJEL2b152RG3ERkuPopZi1LTtQnGPYzU5BbbY85SmcrEtGzWzPR0ty6CU8ewDQraqEHEDBGbiryG4_6rZM8s6tZViHIflQjduGx4bnoQtgXITrfHNjjGSQpOK5TkvrmIN5wrHUHgNj-Q-I5nm-tdBIXgg5rwGLbT0Xj9J2QS6QBz8WjZXws9iFwgDlbWzsvz4ETKLK7Z\" rel=\"nofollow\" target=\"_blank\">LSC_ABIVAX@lifescicomms.com<\/a><\/p>\n<p>\n        <b>Longacre Square Partners <\/b><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=asWw3Utt4Nh9KDbJOSD3x_jSuwEksfDRuacBvnkYF03fyC1ypUA5q-Ibs_Vh1_r9ELffTjLk4MLCuDgSffpPt59sYteV6P670fTAEDEhbudrHdf5dobW77A6QmeWXcqg\" rel=\"nofollow\" target=\"_blank\">Abivax@longacresquare.com<\/a>\n      <\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/b4392994-3935-4249-858a-5fcc92d76be6\">261120_Abivax_PR_Statement Short Seller Report<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZGY0OGMwZjAtNzEwOC00MTg4LWFkNTAtMjdjYzgzOGZhNGRhLTEwMzE2ODktMjAyNi0xMS0yMC1lbg==\/tiny\/Abivax.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abivax Statement on Short Seller Report PARIS, France \u2013 November 20, 2026 \u2013 10:30 PM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax,\u201d the \u201cCompany,\u201d \u201cwe\u201d or \u201cour\u201d), a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026. We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax\u2019s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Abivax Statement on Short Seller Report&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1023046","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abivax Statement on Short Seller Report - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abivax Statement on Short Seller Report - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Abivax Statement on Short Seller Report PARIS, France \u2013 November 20, 2026 \u2013 10:30 PM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax,\u201d the \u201cCompany,\u201d \u201cwe\u201d or \u201cour\u201d), a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026. We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax\u2019s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded &hellip; Continue reading &quot;Abivax Statement on Short Seller Report&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-20T21:35:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abivax Statement on Short Seller Report\",\"datePublished\":\"2026-11-20T21:35:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/\"},\"wordCount\":312,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/\",\"name\":\"Abivax Statement on Short Seller Report - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==\",\"datePublished\":\"2026-11-20T21:35:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-statement-on-short-seller-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abivax Statement on Short Seller Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abivax Statement on Short Seller Report - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/","og_locale":"en_US","og_type":"article","og_title":"Abivax Statement on Short Seller Report - Market Newsdesk","og_description":"Abivax Statement on Short Seller Report PARIS, France \u2013 November 20, 2026 \u2013 10:30 PM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax,\u201d the \u201cCompany,\u201d \u201cwe\u201d or \u201cour\u201d), a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026. We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax\u2019s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded &hellip; Continue reading \"Abivax Statement on Short Seller Report\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-20T21:35:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abivax Statement on Short Seller Report","datePublished":"2026-11-20T21:35:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/"},"wordCount":312,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/","name":"Abivax Statement on Short Seller Report - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==","datePublished":"2026-11-20T21:35:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDc1MCM0MDI1NjcyMjUjMjAyMDExNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-statement-on-short-seller-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abivax Statement on Short Seller Report"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1023046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1023046"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1023046\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1023046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1023046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1023046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}